EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real-life use of isavuconazole in Spanish children and adolescents

Natalia Mendoza-Palomar iD, Silvia Simó Nebot iD, Laura Roig-Soria iD, Laura Alonso García iD, Clara Izquierdo Anto, Marta Taida García Ascaso iD, David Díaz Pérez iD, Carlos Grasa Lozano iD, Cristina Jiménez Núñez iD, Elena María Rincón López iD, Maria Luisa Navarro Gómez iD, Begoña Carazo Gallego iD und 6 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf394 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Natalia Mendoza-Palomar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Hauptthemen laut MEDLINE: Antifungal Agents, Nitriles, Pyridines, Triazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Society of Paediatric Infectious Diseases, Spanish Ministry of Science and Innovation-Instituto de Salud Carlos III and Fondos FEDER, Spanish Ministry of Science and Innovation—Instituto de Salud Carlos III and Fondos FEDER.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Isavuconazole (ISA) has been recently approved for the treatment of invasive aspergillosis and mucormycosis in patients aged >1 year. Prior to this approval, it was used in paediatric patients under compassionate use. The objective of this study is to describe the experience with ISA use in children. Patients and methods A descriptive, retrospective, multicentre study conducted in nine Spanish hospitals, including patients aged ≤18 years who received ≥7 days of ISA between 2018 and 2023. Therapeutic drug monitoring (TDM) was performed with pre-dose [trough concentration (Ctrough)] levels measured according to local protocols. A therapeutic range of 2.5–5 mg/L was used for analysis.

Results

A total of 107 patients (median age: 11 years, 56% male) were included. ISA was used as a treatment (95 patients), mostly as second-line therapy (64 patients, 67%), due to toxicity from previous antifungals (27 patients, 42%). Of 53 patients with proven/probable invasive fungal disease (IFD), 32 (60%) showed a favourable response and 21 (40%) died, 13 due to IFD. Twelve patients received ISA as prophylaxis and none developed breakthrough IFD. Overall, 27/107 (25%) patients experienced adverse effects, the most common being hepatotoxicity, with 10 requiring discontinuation. TDM was performed in 76/95 patients (80%), revealing 59% of Ctrough values outside the therapeutic range.

Conclusions

ISA appears to be a safe and effective option for treating IFD in children, especially when first-line agents have failed or caused excessive toxicity. Although no correlation between Ctrough and clinical outcomes was observed, the significant proportion of patients with out-of-range Ctrough emphasizes the need for TDM in paediatrics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsNitrilesPyridinesTriazolesInvasive Fungal InfectionsMucormycosisHumansMaleChildFemaleAdolescentRetrospective StudiesSpainChild, PreschoolDrug MonitoringAspergillosisInfantTreatment Outcome

Substanzen

isavuconazoleAntifungal AgentsNitrilesPyridinesTriazoles

Autor:innen und Institutionen

  • Paediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Infection and Immunity in Pediatric Patients Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
  • Infectious Diseases and Systemic Inflammatory Response in Paediatrics, Paediatric Infectious Diseases Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Centre for Biomedical Network Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Paediatric Haematology and Oncology Department, Stem Cell Transplant Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Paediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain.

ORCID-Profile: Natalia Mendoza-Palomar, Silvia Simó Nebot, Laura Roig-Soria, Laura Alonso García, Marta Taida García Ascaso, David Díaz Pérez, Carlos Grasa Lozano, Cristina Jiménez Núñez, Elena María Rincón López, Maria Luisa Navarro Gómez, Begoña Carazo Gallego, Beatriz Álvarez Vallejo, Jose Tomás Ramos Amador, Ángela Manzanares, Beatriz Jiménez Montero, Antoni Noguera Julian, Pere Soler-Palacin

Förderung

  • European Society of Paediatric Infectious Diseases
  • Spanish Ministry of Science and Innovation-Instituto de Salud Carlos III and Fondos FEDER
  • Spanish Ministry of Science and Innovation—Instituto de Salud Carlos III and Fondos FEDER

Zitieren

APA

Mendoza-Palomar, N., Simó Nebot, S., Roig-Soria, L., Alonso García, L., Izquierdo Anto, C., García Ascaso, M. T., Díaz Pérez, D., Grasa Lozano, C., Jiménez Núñez, C., Rincón López, E. M., Navarro Gómez, M. L., Carazo Gallego, B., Álvarez Vallejo, B., Ramos Amador, J. T., Manzanares, Á., Jiménez Montero, B., Noguera Julian, A., & Soler-Palacin, P. (2026). Real-life use of isavuconazole in Spanish children and adolescents. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf394

Vancouver

Mendoza-Palomar N, Simó Nebot S, Roig-Soria L, Alonso García L, Izquierdo Anto C, García Ascaso MT, et al. Real-life use of isavuconazole in Spanish children and adolescents. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf394

BibTeX
@article{MendozaPalomar2026,
  author = {Mendoza-Palomar, Natalia and Simó Nebot, Silvia and Roig-Soria, Laura and Alonso García, Laura and Izquierdo Anto, Clara and García Ascaso, Marta Taida and Díaz Pérez, David and Grasa Lozano, Carlos and Jiménez Núñez, Cristina and Rincón López, Elena María and Navarro Gómez, Maria Luisa and Carazo Gallego, Begoña and Álvarez Vallejo, Beatriz and Ramos Amador, Jose Tomás and Manzanares, Ángela and Jiménez Montero, Beatriz and Noguera Julian, Antoni and Soler-Palacin, Pere},
  title = {Real-life use of isavuconazole in Spanish children and adolescents},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf394}
}
Kostenlos starten →